Patents by Inventor Emily C. DYKHUIZEN

Emily C. DYKHUIZEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210315876
    Abstract: This disclosure provides methods of using BAF complex modulating compounds as inhibitors of BAF-mediated transcription in target cells. The BAF complex modulating compounds include 12-membered macrolactam compounds that can target a BAF-specific subunit (e.g., ARID1A) to prevent nucleosomal positioning, relieving transcriptional repression of HIV-1. The subject methods can provide for reversal of latency of HIV-1 in cells in vitro or in vivo. Use of the macrolactam BAF complex modulating compounds represent a method of HIV latency reversal with a unique mechanism of action, which can be optionally combined with other Latency Reversal Agents to improve reservoir targeting. The subject methods can be utilized in conjunction with any convenient methods of treating HIV or HIV latency, including methods related to immune system activation, antiretroviral therapies and/or anti-HIV agents.
    Type: Application
    Filed: July 11, 2019
    Publication date: October 14, 2021
    Inventors: Emily C. Dykhuizen, Gerald R. Crabtree, Tokameh Mahmoudi
  • Publication number: 20210284691
    Abstract: The present invention relates to series of peptidomimetic compounds selectively targeting CBX8 of polycomb chromobox protein homolog proteins. Pharmaceutical compositions of those compounds and methods of using them in the treatment of diseases involved CBX8 pharmacology, including various cancers and leukemia, by administering therapeutically effective amounts of such compound alone or together with other therapeutics, are within the scope of this disclosure.
    Type: Application
    Filed: May 18, 2021
    Publication date: September 16, 2021
    Applicant: Purdue Research Foundation
    Inventors: Casey J Krusemark, Emily C Dykhuizen, Sijie Wang
  • Publication number: 20200385424
    Abstract: The present invention relates to series of peptidomimetic compounds selectively targeting CBX8 of polycomb chromobox protein homolog proteins. Pharmaceutical compositions of those compounds and methods of using them in the treatment of diseases involved CBX8 pharmacology, including various cancers and leukemia, by administering therapeutically effective amounts of such compound alone or together with other therapeutics, are within the scope of this disclosure.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 10, 2020
    Applicant: Purdue Research Foundation
    Inventors: Casey J. Krusemark, Emily C. Dykhuizen, Sijie Wang
  • Publication number: 20200255416
    Abstract: The invention provided here creates a new paradigm for the treatment of a variety of conditions where modulation of a BAF complex is desired. The disclosure that follows outlines a strategy for modulating a BAF complex in a cell, and provides effective compounds, pharmaceutical compositions, development strategies, and treatment protocols, and describes many of the ensuing benefits. A new family of BAF complex modulating compounds has been developed based on a new chemical scaffold including a 12-membered macrolactam core structures. Contacting target cells in vitro or in vivo with the compounds and compositions of this invention can selectively inhibit the activity of BAF complexes in such cells. Some of the BAF complex modulating compounds in this family are particularly effective agents for treating cancer in conjunction with a ATR inhibitor.
    Type: Application
    Filed: September 13, 2018
    Publication date: August 13, 2020
    Inventors: Emma J. CHORY, Gerald R. CRABTREE, Emily C. DYKHUIZEN